Avidity
Kat Lange serves as the Chief Business Officer at Avidity Biosciences, Inc., bringing expertise in strategic business development. Previously, Kat Lange held the position of Chief Financial Officer at Locanabio, Inc., where financial oversight and management were key responsibilities. Additionally, Kat Lange gained valuable experience as a Summer Analyst at Goldman Sachs, contributing to a diverse skill set in finance and business operations.
This person is not in any teams
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.